Values as of: 2025-01-11
COMMON STOCK | Biotechnology |
Last Closing
USD 0.949Change
0.00 (0.00)%Market Cap
USD 0.67BVolume
N/AAnalyst Target
USD 1.80Verdict
Verdict
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Company Website : https://www.pharming.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| ARGNF | argenx SE |
N/A |
USD 39.01B |
| UCBJF | UCB SA |
N/A |
USD 37.94B |
| UCBJY | UCB SA ADR |
N/A |
USD 37.34B |
| GNMSF | Genmab A/S |
N/A |
USD 13.64B |
| WXIBF | WuXi Biologics |
N/A |
USD 8.99B |
| WXXWY | WuXi Biologics (Cayman) Inc |
N/A |
USD 8.93B |
| IVBIY | IVBIY |
N/A |
USD 7.80B |
| SBMFF | Sino Biopharmaceutical Limited |
N/A |
USD 7.48B |
| ZLDPF | Zealand Pharma A/S |
N/A |
USD 7.14B |
| SBHMY | Sino Biopharmaceutical Ltd ADR |
N/A |
USD 6.89B |
N/A
| Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -3.31% | 35% | F | 31% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -3.31% | 35% | F | 31% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | -19.23% | 56% | F | 41% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -19.23% | 56% | F | 39% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | -43.95% | 69% | C- | 42% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -43.95% | 68% | D+ | 39% | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | -3.75% | 44% | F | 31% | F | ||
| Dividend Return | -3.75% | 44% | F | 28% | F | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 29.36% | 89% | A- | 74% | C | ||
| Risk Adjusted Return | -12.77% | 39% | F | 27% | F | ||
| Market Capitalization | 0.67B | 90% | A- | 70% | C- | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total free cash flow in the most recent four quarters.
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The company had negative total cash flow in the most recent four quarters.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
This stock has shown below median earnings growth in the previous 5 years compared to its sector
This stock has shown below median revenue growth in the previous 5 years compared to its sector
